Ernexa Therapeutics Inc. (ERNA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 6, 2026, details a material definitive agreement entered into by Ernexa Therapeutics Inc. to conduct a public offering of equity securities. The offering closed on February 10, 2026.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $10.5 million.
- Securities Issued:
- 19,000,000 shares of Common Stock and accompanying Warrants at $0.50 per unit.
- 2,000,000 Pre-Funded Warrants and accompanying Warrants at $0.49 per unit.
- Placement Agent Fees:
- Cash fee: 6.5% of aggregate purchase price (1.5% for certain existing investors).
- Deferred fee: Cash compensation payable quarterly on warrant exercises.
- Stock fee: 231,576 shares of Common Stock (1.5% of aggregate units sold).
- Expense reimbursement: $125,000 for legal expenses.
- Warrant Terms:
- Symbol: ERNAW (trading commenced February 6, 2026).
- Exercise Price: $0.68 per share.
- Expiration: Earlier of 5-year anniversary or 180 days after Phase 1 clinical data release for ERNA-101.
- Pre-Funded Warrant Terms:
- Exercise Price: $0.01 per share.
- Immediately exercisable subject to ownership limitations.
Material Changes and Use of Proceeds
The filing does not provide comparative financial metrics (revenue, profit, cash flow) as this is a transactional report rather than a periodic financial statement. The primary material change is the increase in capitalization and potential dilution from the issuance of new shares and warrants. The Company intends to use net proceeds to support the advancement of its development programs, working capital, and general corporate purposes.
Guidance, Outlook, and Restrictions
- Lock-Up Agreements: Officers and directors agreed not to sell Common Stock for 90 days following the closing date (February 10, 2026).
- Issuance Restrictions: The Company is restricted from issuing new equity or filing new registration statements for 90 days post-closing, subject to exceptions.
- Variable Rate Transactions: The Company agreed not to enter into Variable Rate Transactions for 90 days post-closing.
- Outlook: Management indicated the capital raise is intended to fund clinical development, specifically referencing the Phase 1 study of ERNA-101 as a trigger for warrant expiration.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 6.5% placement fee, stock issuance, and $125,000 expense reimbursement.
- Confirm the exact number of shares issued to the Placement Agent (231,576) and the impact on fully diluted share count.
- Monitor the timeline for the Phase 1 clinical trial data release for ERNA-101, as this determines the early expiration of the warrants.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the 90-day lock-up and issuance restrictions.
- Assess the dilution impact of the Pre-Funded Warrants, which are immediately exercisable at $0.01.